vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and Dominari Holdings Inc. (DOMH). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $21.2M, roughly 1.4× Autolus Therapeutics plc). Autolus Therapeutics plc runs the higher net margin — -373.3% vs -438.1%, a 64.8% gap on every dollar of revenue.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
AUTL vs DOMH — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $30.1M |
| Net Profit | $-79.1M | $-131.8M |
| Gross Margin | — | — |
| Operating Margin | -337.9% | -8.9% |
| Net Margin | -373.3% | -438.1% |
| Revenue YoY | — | 220.4% |
| Net Profit YoY | 3.6% | -12426.2% |
| EPS (diluted) | $-0.30 | $-6.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $30.1M | ||
| Q3 25 | $21.2M | $50.8M | ||
| Q2 25 | $20.9M | $34.1M | ||
| Q1 25 | $9.0M | $8.1M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | $0 | $4.0M | ||
| Q2 24 | $0 | $6.2M | ||
| Q1 24 | $10.1M | $1.4M |
| Q4 25 | — | $-131.8M | ||
| Q3 25 | $-79.1M | $125.2M | ||
| Q2 25 | $-47.9M | $16.6M | ||
| Q1 25 | $-70.2M | $-32.5M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | $-82.1M | $-4.2M | ||
| Q2 24 | $-58.3M | $-6.1M | ||
| Q1 24 | $-52.7M | $-5.4M |
| Q4 25 | — | -8.9% | ||
| Q3 25 | -337.9% | -3.1% | ||
| Q2 25 | -292.6% | -57.0% | ||
| Q1 25 | -726.3% | -394.6% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | -79.1% | ||
| Q2 24 | — | -44.3% | ||
| Q1 24 | -384.1% | -205.2% |
| Q4 25 | — | -438.1% | ||
| Q3 25 | -373.3% | 246.4% | ||
| Q2 25 | -229.0% | 48.7% | ||
| Q1 25 | -781.1% | -400.5% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | — | -104.2% | ||
| Q2 24 | — | -99.1% | ||
| Q1 24 | -522.1% | -398.0% |
| Q4 25 | — | $-6.94 | ||
| Q3 25 | $-0.30 | $7.27 | ||
| Q2 25 | $-0.18 | $1.12 | ||
| Q1 25 | $-0.26 | $-3.02 | ||
| Q4 24 | — | $0.21 | ||
| Q3 24 | $-0.31 | $-0.67 | ||
| Q2 24 | $-0.22 | $-1.01 | ||
| Q1 24 | $-0.24 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | $80.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $265.5M | $69.4M |
| Total Assets | $661.9M | $112.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $80.5M | ||
| Q3 25 | $86.1M | $176.2M | ||
| Q2 25 | $123.8M | $28.2M | ||
| Q1 25 | $95.8M | $18.9M | ||
| Q4 24 | — | $8.2M | ||
| Q3 24 | $657.1M | $7.2M | ||
| Q2 24 | $705.9M | $12.1M | ||
| Q1 24 | $758.5M | $7.1M |
| Q4 25 | — | $69.4M | ||
| Q3 25 | $265.5M | $210.2M | ||
| Q2 25 | $346.5M | $88.6M | ||
| Q1 25 | $371.1M | $42.4M | ||
| Q4 24 | — | $39.9M | ||
| Q3 24 | $477.0M | $38.3M | ||
| Q2 24 | $527.8M | $42.4M | ||
| Q1 24 | $582.0M | $47.7M |
| Q4 25 | — | $112.9M | ||
| Q3 25 | $661.9M | $223.4M | ||
| Q2 25 | $721.0M | $109.3M | ||
| Q1 25 | $746.3M | $52.3M | ||
| Q4 24 | — | $47.1M | ||
| Q3 24 | $827.5M | $43.4M | ||
| Q2 24 | $853.6M | $49.1M | ||
| Q1 24 | $901.4M | $52.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | $22.7M |
| Free Cash FlowOCF − Capex | $-72.3M | — |
| FCF MarginFCF / Revenue | -341.2% | — |
| Capex IntensityCapex / Revenue | 20.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $22.7M | ||
| Q3 25 | $-67.9M | $-4.9M | ||
| Q2 25 | $-72.8M | $-353.0K | ||
| Q1 25 | $-75.6M | $1.2M | ||
| Q4 24 | — | $-16.7M | ||
| Q3 24 | $-76.7M | $-4.7M | ||
| Q2 24 | $-51.1M | $1.4M | ||
| Q1 24 | $-40.5M | $-8.6M |
| Q4 25 | — | — | ||
| Q3 25 | $-72.3M | — | ||
| Q2 25 | $-80.1M | — | ||
| Q1 25 | $-83.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-86.3M | — | ||
| Q2 24 | $-51.9M | — | ||
| Q1 24 | $-41.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | -341.2% | — | ||
| Q2 25 | -382.6% | — | ||
| Q1 25 | -933.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -406.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 20.8% | — | ||
| Q2 25 | 34.8% | — | ||
| Q1 25 | 91.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.04× | ||
| Q2 25 | — | -0.02× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -15.65× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AUTL
Segment breakdown not available.
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
